Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

ESC Congress 2023 In a large pooled analysis, intravenous ferric carboxymaltose reduced the risk of CV hospitalizations or CV death combined, but not mortality alone, in patients with HFrEF/HFmrEF and iron deficiency.

ESC Congress 2023 In HFrEF patients with iron deficiency, IV ferric carboxymaltose resulted in a modest albeit not statistically significant improvement in the hierarchical composite outcome of all-cause mortality, HF hospitalization, and change in exercise capacity.

ESC Congress 2023 STEP HFpEF showed that once-weekly semaglutide 2.4 mg improved HF-related symptoms, physical limitations and exercise function, and led to greater weight loss in patients with HFpEF and obesity, compared with placebo.

ESC Congress 2023 Well before the next scheduled full ESC guideline on HF, new evidence of several RCTs that should change the management of patients with HF has become available. Therefore, the 2023 Focused Update was presented and published.

ESC Congress 2023 In the RED-CVD trial, it was shown that a proactive diagnostic intervention strategy improves early diagnosis of CVD in primary care patients with COPD and/or T2D.

ESC Heart Failure 2023 Jozine ter Maaten shares the results of a subanalysis of STRONG-HF, which investigated the effects of high intensity HF care on renal function.

ESC Heart Failure 2023 Robert Mentz presents the results of PARAGLIDE-HF, which reported greater reduction in NT-proBNP in the sacubitril/valsartan group vs. the valsartan group in HFmrEF/HFpEF after a worsening HF event.

ESC Heart Failure 2023 Jasper Brugts summarizes the results of the MONITOR-HF trial, which investigated the efficacy of remote hemodynamic monitoring vs. standard care in patients with chronic HF.

In a network meta-analysis, SGLT2i reduced the risk of CV death or HF hospitalization compared with placebo, whereas MRA, ARNI, RAASi, and beta-blocker showed nonsignificant trends towards risk reduction. There was no significant superiority of any drug class.

In a pooled post hoc analysis of DAPA-HF and DELIVER the benefits of dapagliflozin were independent of gout status in patients with HF across the spectrum of LVEF.